The Bergen 4-day treatment for panic disorder: adapting to COVID-19 restrictions with a hybrid approach of face-to-face and videoconference modalities.
B4DT
CBT
Concentrated treatment
Exposure
Panic disorder
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
08 08 2023
08 08 2023
Historique:
received:
01
02
2023
accepted:
28
07
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
The Bergen 4-day treatment (B4DT) is a concentrated exposure-based therapy that has been shown to be effective in the treatment of anxiety disorders. The current study sought to examine the effectiveness of B4DT for panic disorder (PD), when delivered with a combination of face-to-face sessions and videoconferencing. Treatment was delivered to 50 patients from April 2020 to May 2021. Because of regulations during the pandemic, a significant portion of the treatment was conducted via videoconference. The primary outcome measure was the clinician-rated Panic Disorder Severity Scale (PDSS), and secondary measures included patient-rated symptoms of panic disorder, agoraphobia, generalized anxiety, depression, and treatment satisfaction. Changes in symptom levels over time were estimated using multilevel models. Patients showed a significant reduction in clinician-rated symptoms of panic disorder (Measured by PDSS) from before treatment to post treatment (d = 2.18) and 3-month follow-up (d = 2.01). At three months follow-up 62% of patients were classified as in remission, while 70% reported a clinically significant response. We also found a reduction in symptoms of depression and generalized anxiety, and the patients reported high satisfaction with the treatment. The current study suggests that B4DT delivered in a combination of videoconference and face-to-face meetings may be a useful treatment approach. As the study is uncontrolled, future studies should also include more strictly designed investigations.
Sections du résumé
BACKGROUND
The Bergen 4-day treatment (B4DT) is a concentrated exposure-based therapy that has been shown to be effective in the treatment of anxiety disorders. The current study sought to examine the effectiveness of B4DT for panic disorder (PD), when delivered with a combination of face-to-face sessions and videoconferencing.
METHODS
Treatment was delivered to 50 patients from April 2020 to May 2021. Because of regulations during the pandemic, a significant portion of the treatment was conducted via videoconference. The primary outcome measure was the clinician-rated Panic Disorder Severity Scale (PDSS), and secondary measures included patient-rated symptoms of panic disorder, agoraphobia, generalized anxiety, depression, and treatment satisfaction. Changes in symptom levels over time were estimated using multilevel models.
RESULTS
Patients showed a significant reduction in clinician-rated symptoms of panic disorder (Measured by PDSS) from before treatment to post treatment (d = 2.18) and 3-month follow-up (d = 2.01). At three months follow-up 62% of patients were classified as in remission, while 70% reported a clinically significant response. We also found a reduction in symptoms of depression and generalized anxiety, and the patients reported high satisfaction with the treatment.
CONCLUSION
The current study suggests that B4DT delivered in a combination of videoconference and face-to-face meetings may be a useful treatment approach. As the study is uncontrolled, future studies should also include more strictly designed investigations.
Identifiants
pubmed: 37550696
doi: 10.1186/s12888-023-05062-7
pii: 10.1186/s12888-023-05062-7
pmc: PMC10408203
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
570Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Eur Psychiatry. 2010 Apr;25(3):172-7
pubmed: 19553089
Respir Physiol Neurobiol. 2020 Nov;282:103530
pubmed: 32818605
J Affect Disord. 2015 Mar 15;174:19-22
pubmed: 25479049
Cogn Behav Ther. 2019 Mar;48(2):89-105
pubmed: 30088441
Front Psychol. 2018 Jun 26;9:1044
pubmed: 29997546
Behav Res Ther. 1985;23(1):35-44
pubmed: 3985915
Behav Res Ther. 1986;24(4):461-70
pubmed: 3741311
J Consult Clin Psychol. 1984 Dec;52(6):1090-7
pubmed: 6520279
Behav Res Ther. 2006 Jun;44(6):807-17
pubmed: 16084488
BMC Psychiatry. 2023 May 1;23(1):305
pubmed: 37127598
JAMA Netw Open. 2020 Aug 3;3(8):e2013249
pubmed: 32789516
Br J Psychiatry. 2002 May;180:461-4
pubmed: 11983645
Psychol Med. 2022 Oct;52(14):3222-3230
pubmed: 33436120
Psychother Res. 2009 Jul;19(4-5):438-52
pubmed: 20183399
Front Psychol. 2018 May 03;9:639
pubmed: 29774005
J Public Health (Oxf). 2020 Nov 23;42(4):672-678
pubmed: 32657323
Cogn Behav Ther. 2020 Jul;49(4):270-293
pubmed: 31303121
Nord J Psychiatry. 2019 Jan;73(1):58-63
pubmed: 30636466
Depress Anxiety. 2009;26(10):922-9
pubmed: 19006198
BMC Psychiatry. 2022 Nov 23;22(1):728
pubmed: 36418989
Psychol Methods. 2002 Mar;7(1):105-25
pubmed: 11928886
Front Psychol. 2019 Nov 15;10:2500
pubmed: 31803089
Behav Ther. 2011 Dec;42(4):689-99
pubmed: 22035997
Psychol Med. 2018 Sep;48(12):1945-1953
pubmed: 29368665
BMC Psychiatry. 2018 Oct 4;18(1):323
pubmed: 30286745
Arch Gen Psychiatry. 2006 Apr;63(4):415-24
pubmed: 16585471
Behav Res Ther. 2017 Oct;97:134-145
pubmed: 28772195
Eval Program Plann. 1979;2(3):197-207
pubmed: 10245370
Front Psychol. 2020 May 27;11:982
pubmed: 32528372
Psychother Res. 2009 Jul;19(4-5):429-37
pubmed: 19235088
Lancet. 2017 Dec 17;388(10063):3048-3059
pubmed: 27349358
Clin Psychol Psychother. 2011 May-Jun;18(3):234-43
pubmed: 21110405
J Psychiatr Res. 2001 Sep-Oct;35(5):293-6
pubmed: 11591432
Compr Psychiatry. 2005 May-Jun;46(3):223-8
pubmed: 16021593